Copertina

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"

Salvato in:

Dettagli Bibliografici
Autori principali:	Kim Rand (Autore), Juan Manuel Ramos-Goñi (Autore), Bülent Akmaz (Autore), Laia Solé-Feu (Autore), José-Carlos A (Autore)
Natura:	Libro
Pubblicazione:	Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
Soggetti:	article
Accesso online:	Connect to this object online.
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
di: Kim Rand, et al.
Pubblicazione: (2023)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
di: Kim Rand, et al.
Pubblicazione: (2024)

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'
di: Mike Bastian, et al.
Pubblicazione: (2024)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
di: Tiago Torres, et al.
Pubblicazione: (2024)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
di: Labib A, et al.
Pubblicazione: (2022)

Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs
di: Francisco Javier Parrondo-García, et al.
Pubblicazione: (2021)

Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences
di: Jill I. Olydam, et al.
Pubblicazione: (2022)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis
di: Takeshi Nakahara, et al.
Pubblicazione: (2024)

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
di: Gil Yosipovitch, et al.
Pubblicazione: (2024)

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
di: James Signorovitch, et al.
Pubblicazione: (2023)

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
di: Jinger Lin, et al.
Pubblicazione: (2024)

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
di: Jonathan I. Silverberg, et al.
Pubblicazione: (2024)

Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
di: Akio Tanaka, et al.
Pubblicazione: (2024)

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
di: Peter A. Lio, et al.
Pubblicazione: (2024)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
di: April W. Armstrong, et al.
Pubblicazione: (2024)

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
di: Ronan Mahon, et al.
Pubblicazione: (2024)

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
di: Lieneke F.M. Ariëns, et al.
Pubblicazione: (2019)

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
di: April W. Armstrong, et al.
Pubblicazione: (2024)

Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
di: Max Schlueter, et al.
Pubblicazione: (2024)

Experience with dupilumab in patients with atopic dermatitis
di: E. A. Glukhova, et al.
Pubblicazione: (2023)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
di: Angela J. Okragly, et al.
Pubblicazione: (2023)

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
di: Jonathan I. Silverberg, et al.
Pubblicazione: (2024)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
di: April W. Armstrong, et al.
Pubblicazione: (2023)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
di: Nick Ballew, et al.
Pubblicazione: (2022)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
di: Amy S. Paller, et al.
Pubblicazione: (2023)

Efficacy of dupilumab in moderate and severe atopic dermatitis
di: Stephan Weidinger, et al.
Pubblicazione: (2023)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
di: Shan J, et al.
Pubblicazione: (2022)

Alopecia areata after dupilumab for atopic dermatitis
di: Krystal Mitchell, MBA, et al.
Pubblicazione: (2018)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
di: Amanda E. Zubek, MD, PhD, et al.
Pubblicazione: (2021)

A review of dupilumab in the treatment of atopic diseases
di: Quinn Thibodeaux, et al.
Pubblicazione: (2019)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
di: Sandra Ferreira, et al.
Pubblicazione: (2020)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
di: April W. Armstrong, et al.
Pubblicazione: (2023)

Letter to the editor
di: Sagrika Shukla, et al.
Pubblicazione: (2023)

Letters to the Editor
Pubblicazione: (1996)

Letter to Editor
di: Ayesha Aslam, et al.
Pubblicazione: (2020)

Letter to the Editor
di: Mohandas Bhat
Pubblicazione: (2013)

Letter to Editor
di: Zbys Fedorowicz
Pubblicazione: (2008)

Letter to the Editor
di: Pål Wölner-Hanssen
Pubblicazione: (1996)

Letters to the Editor
di: Elliott M. Levine
Pubblicazione: (2001)

Letter to the Editor
di: Manvin S. Amstey
Pubblicazione: (2000)